pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

4,284 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT1787Endpoints1391Fierce Biotech711BioSpace702BioPharma Dive526raps234onclive165fda recalls
therapy area
allOncology12335Rare Disease3228Immunology2872Cardiology2752Hematology2179Pulmonology2149Vaccines
  • Journalist reflects on challenges of reporting healthcare AI after fellowship
    The author participated in a journalism fellowship that focused on health technology reporting. The experience underscored the importance of continuously examining the incentives that drive AI pro…
    Endpoints · 6mo agoNeutral↗ source
  • PCOS renamed PMOS after decade-long scientific effort
    A new name for the condition formerly known as polycystic ovary syndrome (PCOS) has been introduced. The term polyendocrine metabolic ovarian syndrome (PMOS) was presented in a paper published in…
    STAT · 6mo agoPositive↗ source
← prev
page 159 of 172
next →
113
fda medwatch111
globenewswire health73
fda press59
1802
Psychiatry & CNS1204
Ophthalmology1062
Pain778
Endocrinology & Metabolism777
Nephrology762
CSL shares plunge to nine-year low after cutting revenue forecast and announcing $5 billion impairment
CSL's shares fell to their lowest level since early 2017 after the company reduced its full‑year revenue guidance by roughly four percent. The guidance cut signals slower sales growth than previous…
Endpoints · 6mo agoEarningsNegative↗ source
  • Rezdiffra Beats Wall Street Forecasts as MASH Market Expands
    Rezdiffra, a drug candidate targeting metabolic dysfunction‑associated steatohepatitis (MASH), is outperforming analysts' expectations according to recent commentary. The optimism comes as the mar…
    Endpoints · 6mo agoPositive↗ source
  • Astellas revisits gene therapy for XLMTM, offering new hope after earlier setbacks
    A gene therapy for the rare muscle disorder X‑linked myotubular myopathy (XLMTM) showed mixed results in early trials, with some boys experiencing dramatic recoveries while others died. Astellas P…
    STAT · 6mo agoPositive↗ source
  • Supreme Court pauses restrictions, keeps abortion pill mifepristone available through pharmacies and mail
    The Supreme Court issued an order that maintains current access to the abortion medication mifepristone while it reviews a case challenging FDA prescribing rules. The order, signed by Justice Samu…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Colombian court upholds compulsory license for HIV drug, affirming legal framework
    The Court of Justice of the Andean Community ruled that Colombia's issuance of a compulsory license for an HIV medicine two years ago was lawful. The tribunal said the government had a valid publi…
    STAT · 6mo agoRegulatoryPositive↗ source
  • Medicare falls short on projected Alzheimer’s drug costs as fewer seniors use Leqembi
    Bob Herman reports that Medicare's earlier estimate that the new Alzheimer's therapy Leqembi would cost the program $3.5 billion in 2025 has proved far too high. The agency's actuaries based the fo…
    STAT · 6mo agoRegulatoryNegative↗ source
  • FDA policy lets some flavored vapes stay on shelves without full approval, raising expert concerns
    The Food and Drug Administration announced a new guidance that allows certain flavored e-cigarettes and nicotine pouches to remain on the market even though they have not received full authorizatio…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Daiichi Sankyo targets $15 billion in oncology sales by 2030 as it expands ADC franchise
    Daiichi Sankyo released a new five‑year business plan that sets a goal of nearly $15 billion in oncology revenue by 2030. The target is part of a broader ambition to push total company sales past 3…
    Endpoints · 6mo agoNeutral↗ source
  • Inhibrx reports combo of Keytruda and INBRX-106 reduces tumors more than Keytruda alone in metastatic head cancer
    San Diego biotech Inhibrx says its experimental drug INBRX-106, when added to Merck's immunotherapy Keytruda, led to a higher rate of tumor shrinkage than Keytruda by itself. The observation comes…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • Astellas therapy brings new hope to rare disease patients amid broader biotech challenges
    A new Astellas treatment is being highlighted as a source of optimism for a community affected by a rare disease, after a period of setbacks in the program. The article also notes a revived gene t…
    STAT · 6mo agoPositive↗ source
  • Braveheart Bio's Hengrui-licensed cardiac therapy shows positive mid-stage trial results
    Braveheart Bio announced that its heart muscle therapy, licensed from Jiangsu Hengrui Pharmaceuticals, has achieved a positive outcome in a Phase 2 trial. The mid-stage study met its primary endpo…
    Endpoints · 6mo agoPositive readoutPositive↗ source
  • Medicare uptake of newly approved Alzheimer’s drugs Leqembi and Kisunla falls short of expectations
    Medicare is seeing much lower use of the two Alzheimer’s treatments that received FDA approval earlier this year. The drugs, Leqembi and Kisunla, were expected to generate notable spending for Med…
    STAT · 6mo agoRegulatoryNegative↗ source
  • European regulators approve Fractyl Health's first GLP-1 gene therapy clinical trial
    European regulators have given the green light for Fractyl Health, a biotech near Boston, to begin its first human study of a GLP-1 gene therapy. The therapy aims to provide a one-time treatment t…
    Endpoints · 6mo agoRegulatoryPositive↗ source
  • Experts call for licensing framework as Utah pauses AI chatbot prescription program
    Alon Bergman, an assistant professor of medical ethics at the University of Pennsylvania, argues that AI-driven medical tools need a licensing system. He points to Utah’s recent pilot with the AI c…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • Medicare cuts projected spending on new Alzheimer’s drugs as uptake remains low
    Medicare is spending far less on the recently approved Alzheimer’s treatments Leqembi and Kisunla than officials had anticipated. The Centers for Medicare and Medicaid Services said the agency does…
    STAT · 6mo agoRegulatoryNegative↗ source
  • Optum Rx Announces Transparent Pharmacy Model Set to Launch in 2027
    Optum Rx, a unit of UnitedHealth Group, introduced a new pharmacy benefit model that promises clear fee structures for its customers. The model is designed to give members visibility into the full…
    Endpoints · 6mo agoPositive↗ source
  • Novo Nordisk secures biotech partner for Parkinson's cell therapy as GSK signs hepatitis B drug deal in China
    Novo Nordisk has found a biotech partner to advance its early‑stage Parkinson's disease cell therapy, giving the program a new development home. GSK disclosed a commercial agreement to sell its he…
    Endpoints · 6mo agoDealNeutral↗ source
  • Providers and insurers vie to influence upcoming No Surprises Act arbitration rule
    The federal government is preparing to release a final rule that will reshape the arbitration process under the No Surprises Act. Health care providers and insurers are both scrambling to have thei…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • President Trump says government may consider approving certain forms of kratom-derived 7-OH
    President Trump suggested the federal government could move to approve some forms of 7-OH, an opioid derived from the kratom plant. 7-OH, short for 7-hydroxymitragynine, occurs naturally in kratom…
    STAT · 6mo agoRegulatoryNeutral↗ source
  • FDA commissioner Marty Makary faces possible dismissal amid political pressure, while new insights link menstrual cycles to mental health
    Theresa Gaffney’s Morning Rounds newsletter highlighted a growing body of research that connects menstrual cycle patterns with fluctuations in mental health, underscoring the importance of gender‑s…
    STAT · 6mo agoNeutral↗ source
  • AI dependence mirrors addiction, warns psychiatrist, sparking debate on hidden costs
    Jonathan Avery, vice chair for addiction psychiatry at Weill Cornell Medicine, reflects on his podcast about addiction and the mixed feedback he receives. In a recent episode he interviewed NYU ne…
    STAT · 6mo agoNeutral↗ source
  • Dermatophilosis identified in clusters of European gay men, a mild livestock skin disease
    Researchers in France and Spain have diagnosed several men who have sex with men with dermatophilosis, a bacterial skin infection normally seen in livestock. The cases occurred without any known c…
    STAT · 6mo agoNeutral↗ source
  • Experts criticize CDC's limited role as hantavirus outbreak spreads on cruise ship
    Health officials are dealing with a hantavirus outbreak affecting passengers on a cruise ship, and the World Health Organization has taken the lead in coordinating the response. The U.S. Centers fo…
    STAT · 6mo agoRegulatoryNegative↗ source